ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12, Bloomberg Earnings reports. The firm had revenue of $48.16 million during the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm’s revenue was up 25.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.09 EPS. ANI Pharmaceuticals updated its FY17 guidance to $3.83-4.00 EPS.
ANI Pharmaceuticals (NASDAQ ANIP) opened at $61.97 on Friday. The stock has a market capitalization of $721.52 million, a P/E ratio of 17.78 and a beta of 2.84. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $65.81. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.49 and a current ratio of 3.45.
Several research firms have issued reports on ANIP. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity reiterated a “buy” rating on shares of ANI Pharmaceuticals in a research report on Thursday. Finally, BidaskClub upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $67.33.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
What are top analysts saying about ANI Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ANI Pharmaceuticals Inc. and related companies.